EGFR and neoplasm: This requirement is more difficult to implement in clinical setting as it requires repeated tumor biopsies or reliable surrogate biomarkers (for example, analysis of hair follicles biopsies for EGFR phosphorylation and GLI levels to control pharmacodynamics of EGFR and Hedgehog inhibitors) [269,270].